1. Home
  2. APLM vs DSS Comparison

APLM vs DSS Comparison

Compare APLM & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • DSS
  • Stock Information
  • Founded
  • APLM 2016
  • DSS 1984
  • Country
  • APLM United States
  • DSS United States
  • Employees
  • APLM N/A
  • DSS N/A
  • Industry
  • APLM Blank Checks
  • DSS Containers/Packaging
  • Sector
  • APLM Finance
  • DSS Consumer Discretionary
  • Exchange
  • APLM Nasdaq
  • DSS Nasdaq
  • Market Cap
  • APLM 7.7M
  • DSS 8.0M
  • IPO Year
  • APLM N/A
  • DSS N/A
  • Fundamental
  • Price
  • APLM $6.56
  • DSS $0.95
  • Analyst Decision
  • APLM Strong Buy
  • DSS
  • Analyst Count
  • APLM 1
  • DSS 0
  • Target Price
  • APLM $200.00
  • DSS N/A
  • AVG Volume (30 Days)
  • APLM 57.9K
  • DSS 13.4K
  • Earning Date
  • APLM 04-03-2025
  • DSS 05-13-2025
  • Dividend Yield
  • APLM N/A
  • DSS N/A
  • EPS Growth
  • APLM N/A
  • DSS N/A
  • EPS
  • APLM N/A
  • DSS N/A
  • Revenue
  • APLM $198,000.00
  • DSS $19,097,000.00
  • Revenue This Year
  • APLM $415.15
  • DSS N/A
  • Revenue Next Year
  • APLM N/A
  • DSS N/A
  • P/E Ratio
  • APLM N/A
  • DSS N/A
  • Revenue Growth
  • APLM N/A
  • DSS N/A
  • 52 Week Low
  • APLM $4.71
  • DSS $0.77
  • 52 Week High
  • APLM $49.00
  • DSS $1.94
  • Technical
  • Relative Strength Index (RSI)
  • APLM 50.05
  • DSS 53.59
  • Support Level
  • APLM $5.41
  • DSS $0.86
  • Resistance Level
  • APLM $6.19
  • DSS $1.00
  • Average True Range (ATR)
  • APLM 0.76
  • DSS 0.06
  • MACD
  • APLM 0.10
  • DSS 0.00
  • Stochastic Oscillator
  • APLM 86.05
  • DSS 70.83

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About DSS DSS Inc.

DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia. Product packaging manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the securities trading and/or fund management arena.

Share on Social Networks: